SGS announces that its Life Science Services division has selected Vitalea Science as a partner for providing Microdosing studies based on the Accelerator Mass Spectrometry (AMS) technology. This partnership further strengthens the complementary services offered by both SGS and Vitalea in executing early clinical trials based on the exploratory-IND concept.
Within the past three years, early phase clinical trials (Phase I-IIa) have evolved in process and purpose. New technology applications and shifts in the traditional drug development paradigm allow more information about drug candidates to be captured earlier in the process.
By harnessing the power of the AMS atom counter, one is able to collect ADME, bioavailability, and pharmacokinetic evaluations at the very earliest stages of clinical drug development: Phase 0 microdosing and Phase I microtracing. Streamlining early clinical development with microdosing and microtracers enables better development decisions, increasing potential success while reducing costs of failure for new drugs, formulations and delivery strategies.
In partnering with Vitalea Science, SGS is able to combine its own state of the art Phase I and bioanalytical facilities with Vitalea's AMS technology to provide clients with the necessary tools to execute these microdosing and microtracing studies. With new regulations in place as of June 2007, these exploratory IND studies can now be executed in SGS' Belgian facility.